Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.55 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.55 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.51 |
| ▸ | HRAS | P01112 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HEXA | P06865 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992233 | 0.87 | MAPK1 (0.60) | MAPK1LGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL14544300 | 0.87 | MAPK1 (0.58) | MAPK1MEN1KMT2AHRASPOLB | |
| SCHEMBL542627 | 0.87 | MAPK1 (0.58) | MAPK1MEN1KMT2AHRASPOLB | |
| SCHEMBL14520980 | 0.87 | MAPK1 (0.58) | MAPK1MEN1KMT2AHRASPOLB | |
| SCHEMBL5841792 | 0.87 | MAPK1 (0.58) | MAPK1MEN1KMT2AHRASPOLB | |
| SCHEMBL7150940 | 0.87 | MAPK1 (0.58) | MAPK1MEN1KMT2AHRASPOLB | |
| SCHEMBL13031052 | 0.87 | MAPK1 (0.58) | MAPK1MEN1KMT2AHRASPOLB | |
| SCHEMBL20643560 | 0.87 | MAPK1 (0.58) | MAPK1MEN1KMT2AHRASPOLB | |
| SCHEMBL21097246 | 0.87 | MAPK1 (0.58) | MAPK1MEN1KMT2AHRASPOLB | |
| SCHEMBL542635 | 0.87 | MAPK1 (0.58) | MAPK1MEN1KMT2AHRASPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | MAPK1 4769/4885LGALS8 21/4885LGALS3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.